Category: 72364-46-6

On October 11, 2001, Muehlman, Anna; Classon, Bjoern; Hallberg, Anders; Samuelsson, Bertil published an article.Application of 72364-46-6 The title of the article was Synthesis of potent C2-symmetric, diol-based HIV-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1′ substituents. And the article contained the following:

The synthesis of novel, potent diol-based HIV-1 protease inhibitors, having either -SAr (Ar = Ph, 2-FC6H4, 2-pyridinyl, 2-thienyl), -SCH2Ar (Ar = Ph, 2-FC6H4), or -SCH2R (R = H2C:CHCH2) groups as P1/P1′ substituents is described. They can be prepared using a straightforward synthesis involving a thiol nucleophilic ring opening of a diepoxide. Inhibitor I, an indanyl(thiophenylsulfanyl)hexanediamide, was found to be a potent inhibitor of HIV-1 PR, showing good antiviral activity in a cell-based assay. The experimental process involved the reaction of (2-Fluorophenyl)methanethiol(cas: 72364-46-6).Application of 72364-46-6

The Article related to thioalkyl hexanediamide indanyl methylcarbamoylpropyl preparation hiv protease inhibitor, thioaryl hexanediamide indanyl methylcarbamoylpropyl preparation hiv protease inhibitor, hiv protease inhibitor thioaryl thioalkyl hexanediamide preparation, aids agent thioaryl thioalkyl hexanediamide and other aspects.Application of 72364-46-6

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On September 12, 2003, Bloom, Laura Anne; Boritzki, Theordore James; Kung, Pei-Pei; Ogden, Richard Charles; Skalitzky, Donald James; Zehnder, Luke Raymond; Kuhn, Leslie Ann; Meng, Jerry Jialun published a patent.Computed Properties of 72364-46-6 The title of the patent was Combination therapies for treating methylthioadenosine phosphorylase deficient cells. And the patent contained the following:

The invention is directed to combination therapies for treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an inhibitor of de novo inosinate synthesis and an anti-toxicity agent. The inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase (GARFT) and/or aminoinidazolecarboximide ribonucleotide formyltransferase (AICARFT). The anti-toxicity agent is an MTAP substrate [e.g., methylthioadenosine (MTA)], a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate. Glutamic acid derivative I is claimed as an example of a GARFT inhibitor and compounds II (R1, R2 = H or phosphate or sodium salts, carbamoyl, acyl, carboxy group or esters) are claimed as examples of anti-toxicity agents. Syntheses of these compounds is described and their use in combination therapy studied, e.g., data are given for the growth inhibitory effect of I in vitro on MTAP-competent and MTAP-deficient cells with and without methylthioadenosine as anti-toxicity agent. The experimental process involved the reaction of (2-Fluorophenyl)methanethiol(cas: 72364-46-6).Computed Properties of 72364-46-6

The Article related to combination therapy treatment methylthioadenosine phosphorylase deficient cell, pyridopyrimidinylethylthienoylglutamic acid derivative preparation cytotoxicity crystal structure, glutamic acid pyridopyrimidinylethylthienoyl preparation cytotoxicity crystal structure, antitumor pyridopyrimidinylethylthienoylglutamic acid derivative preparation and other aspects.Computed Properties of 72364-46-6

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts